The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase I/II study of cetuximab (cet) in combination with S-1 and oxaliplatin (SOX) in first-line treatment for metastatic colorectal cancer (mCRC) (JACCRO CC-06).
Akihito Tsuji
Honoraria - Bristol-Myers Squibb; Merck; Taiho Pharmaceutical; Yakult
Yu Sunakawa
No relevant relationships to disclose
Tadamichi Denda
No relevant relationships to disclose
Yasutaka Takinishi
No relevant relationships to disclose
Masahito Kotaka
Honoraria - Bristol-Myers Squibb; Merck; Taiho Pharmaceutical; Yakult
Hiroaki Tanioka
No relevant relationships to disclose
Ken Shimada
No relevant relationships to disclose
Mitsugu Kochi
Honoraria - Taiho Pharmaceutical; Yakult
Takanori Watanabe
No relevant relationships to disclose
Masato Nakamura
Honoraria - Bristol-Myers Squibb; Taiho Pharmaceutical; Yakult
Hiroto Ueda
No relevant relationships to disclose
Michio Inukai
No relevant relationships to disclose
Toshiki Masuishi
No relevant relationships to disclose
Satoshi Tani
No relevant relationships to disclose
Yuji Negoro
No relevant relationships to disclose
Tatsuya Okuno
No relevant relationships to disclose
Masahiro Takeuchi
Consultant or Advisory Role - Merck; Taiho Pharmaceutical
Wataru Ichikawa
Honoraria - Bristol-Myers Squibb; Merck; Taiho Pharmaceutical; Yakult
Masashi Fujii
Consultant or Advisory Role - Taiho Pharmaceutical
Stock Ownership - Eisai (I); Takeda (I)
Honoraria - Taiho Pharmaceutical; Yakult
Toshifusa Nakajima
No relevant relationships to disclose